Van BellenBBamberLCorrea de CarvalhoF. Reduction in length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin2014;30:829-37.
6.
ScarvelisDWellsP. Diagnosis and treatment of deep-vein thrombosis. CMAJ2006;175(9):1087-92.
7.
Garcia-SanzMTPena-AlvarezCLopez-LandeiroP. Symptoms, location and prognosis of pulmonary embolism. Rev Port Pneumol2014;20(4):194-9.
BrowseNLThomasML. Source of non-lethal pulmonary emboli. Lancet1974;1:258-9.
10.
GeertsWHPineoGFHeitJA. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004;126(3 suppl.):338S-400S.
11.
WellsPSAndersonDRBormanisJ. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet1997;350(9094):1795-8.
12.
WellsPSAndersonDRRodgerMJ. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med2003;349:1227-35.
13.
GoldhaberSZBounameauxH. Pulmonary embolism and deep vein thrombosis. Lancet2012;379:1835-46.
14.
KearonC. A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism. J Thromb Haemost2012;10:507-11.
15.
Dalteparin. In: E-Therapeutics +:e-CPS. Ottawa (ON): Canadian Pharmacists Association; 2016. Available: https://www.e-therapeutics.ca/search# (accessed Aug. 20, 2015).
16.
Enoxaparin. In: E-Therapeutics +:e-CPS. Ottawa (ON): Canadian Pharmacists Association; 2016. Available: https://www.e-therapeutics.ca/search# (accessed Aug. 20, 2015).
17.
Fondaparinux. In: E-Therapeutics +:e-CPS. Ottawa (ON): Canadian Pharmacists Association; 2016. Available: https://www.e-therapeutics.ca/search# (accessed Aug. 20, 2015).
18.
Heparin. In: E-Therapeutics +:e-CPS. Ottawa (ON): Canadian Pharmacists Association; 2016. Available: https://www.e-therapeutics.ca/search# (accessed Aug. 20, 2015).
19.
Tinzaparin. In: E-Therapeutics +:e-CPS. Ottawa (ON): Canadian Pharmacists Association; 2016. Available: https://www.e-therapeutics.ca/search# (accessed Aug. 20, 2015).
20.
AgnelliGBullerHCohenA. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med2013;369:799-808.
21.
Einstein Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med2010;363:2499-510.
22.
Einsten PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med2012;366:1287-97.
23.
SchulmanSKearonCKakkarAK. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med2009;361:2342-52.
24.
SchulmanSKearonCKakkarAK. Treatment of acute venous thromboembolism with dabigatran versus warfarin an pooled analysis. Circulation2014;129:764-72.
25.
Coumadin. In: E-Therapeutics +:e-CPS. Ottawa (ON): Canadian Pharmacists Association; 2016. Available: https://www.e-therapeutics.ca/search# (accessed Aug. 20, 2015)
26.
HolbrookASchulmanSWittDM. Evidence-based management of anticoagulant therapy. Chest2012;141(2 suppl.):e152S-84S.
27.
KearonCAklEAOrnelasJ. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest2016;149(2):315-52.
28.
BungardTJYakiwchukEFoisyMBrocklebankC. Drug interactions involving warfarin: practice tool with practical management tips. Can Pharm J (Ott)2011;144(1):21-25e.9.
29.
FrostCWangJNepalS. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol2013;75:476-87.
30.
MooreKTVaidyanathanSDamarajuCVFieldsLE. Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Clin Pharmacol Drug Dev2014;3(4):321-7.
31.
StainMSchonauerVMinarE. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost2005;3(12):2671-6.
AgnelliGBullerHRCohenA. Apixaban for extended treatment of venous thromboembolism. N Engl J Med2013;368:699-708.
34.
SchulmanSKearonCKakkarAK. Extended use of dabigatran, warfarin or placebo in venous thromboembolism. N Engl J Med2013;368:709-18.
35.
ClinicalTrials.gov. Reduced-dose rivaroxaban in the long-term prevention of recurrent symptomatic VTE (venous thromboembolism) (EinsteinChoice). Available: https://clinicaltrials.gov/ct2/show/NCT02064439 (accessed Dec. 4, 2015)
36.
BecattiniCAgnelliGSchenoneA. Aspirin for preventing the recurrence of venous thromboembolism. N Eng J Med2012;366:1959-67.
37.
BrightonTAEikelboomJWMannK. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med2012;367:1979-87.
38.
BungardTJBoltJThomsonP. Checklists for the use of novel oral anticoagulants by the front-line clinician. Can Pharm J (Ott)2015;148(5):241-5.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
